Tissue-based immune monitoring II: Multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma

Cancer Biology and Therapy

Volumn 12, Issue 4, 2011, Pages 367-377

  Hagemann, Andrea R ^a   Hagemann, Ian S ^a   Cadungog, Mark ^a   Hwang, Wei Ting ^a   Patel, Priya ^a   Lal, Priti ^a   Hammond, Rachel ^a   Gimotty, Phyllis A ^a   Chu, Christina S ^a   Rubin, Stephen C ^a   Birrer, Michael J ^b   Powell Jr , Daniel J ^a   Feldman, Michael D ^a   Coukos, George ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adoptive immunotherapy; Lymphocytes; Metastasis; Microarray analysis; Ovarian neoplasms; Tumor infiltrating

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; CELL MARKER; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN PRESENTATION; ARTICLE; CANCER INFILTRATION; CYTOKINE PRODUCTION; CYTOREDUCTIVE SURGERY; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; METASTASIS; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; STROMA CELL; SURVIVAL; T LYMPHOCYTE; TISSUE MICROARRAY; TUMOR BIOPSY;

AGED; ANTIGENS, CD3; ANTIGENS, CD4; ANTIGENS, CD8; CLUSTER ANALYSIS; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; EPITHELIAL CELLS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; MONITORING, IMMUNOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STROMAL CELLS; TISSUE ARRAY ANALYSIS;

EID: 84860389086     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.4.16908     Document Type: Article

References (33)

1. Brill T.H., Kubler H.R., Pohla H., Buchner A., Fend F., Schuster T., et al. Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial. Hum Gene Ther 2009; 20:1641-51; PMID:19671000; DOI:10.1089/hum.2009.101.
2. Redfern C.H., Guthrie T.H., Bessudo A., Densmore J.J., Holman P.R., Janakiraman N., et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol 2006; 24:3107-12; PMID:16754937; DOI:10.1200/JCO.2005.04.4289.
3. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126-9; PMID:16946036; DOI:10.1126/science.1129003.
4. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., Dudley ME Adoptive cell transfer: a clinical path to effective cancer immunotherapy Nat Rev Cancer 2008; 8:299-308; PMID:18354418; DOI:10.1038/nrc2355.
5. Linette G.P., Zhang D., Hodi F.S., Jonasch E.P., Longerich S., Stowell C.P., et al. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Clin Cancer Res 2005; 11:7692-9; PMID:16278389; DOI:10.1158/1078-0432.CCR-05- 1198.
6. Czerniecki B.J., Koski G.K., Koldovsky U., Xu S., Cohen P.A., Mick R., et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007; 67:1842-52; PMID:17293384; DOI:10.1158/0008-5472.CAN-06-4038.
7. Clay T.M., Hobeika A.C., Mosca P.J., Lyerly H.K., Morse M.A. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 2001; 7:1127-1135; PMID:11350875.
8. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-13; PMID:12529460; DOI:10.1056/NEJMoa020177.
9. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; PMID:15322536; DOI:10.1038/nm1093.
10. Adams S.F., Levine D.A., Cadungog M.G., Hammond R., Facciabene A., Olvera N., et al. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 2009; 115:2891-902; PMID:19472394; DOI:10.1002/cncr.24317.
11. Clarke B., Tinker A.V., Lee C.H., Subramanian S., Van de Rijn M., Turbin D., et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss. Mod Pathol 2009; 22:393-402; PMID:19060844; DOI:10.1038/modpathol.2008.191.
12. + T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007; 104:3360-5; PMID:17360651; DOI:10.1073/pnas.0611533104.
13. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102:18538-43; PMID:16344461; DOI:10.1073/pnas.0509182102.
14. Shah C.A., Allison K.H., Garcia R.L., Gray H.J., Goff B.A., Swisher EM Intratumoral T cells, tumor-associated macrophages and regulatory T cells: Association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer Gynecol Oncol 2008; 109:215-9; PMID:18314181; DOI:10.1016/j.ygyno.2008.01.010.
15. + tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008; 108:415-20; PMID:18037158; DOI:10.1016/j.ygyno. 2007.10.016.
16. Stumpf M., Hasenburg A., Riener M.O., Jutting U., Wang C., Shen Y., et al. Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer 2009; 101:1513-21; PMID:19861998; DOI:10.1038/sj.bjc. 6605274.
17. Milne K., Kobel M., Kalloger S.E., Barnes R.O., Gao D., Gilks C.B., et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE 2009; 4:6412; PMID:19641607; DOI:10.1371/journal.pone.0006412.
18. Schlienger K., Chu C.S., Woo E.Y., Rivers P.M., Toll A.J., Hudson B., et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003; 9:1517-1527; PMID:12684428.
19. Goodell V., Salazar L.G., Urban N., Drescher C.W., Gray H., Swensen R.E., et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol 2006; 24:762-8; PMID:16391298; DOI:10.1200/JCO.2005.03.2813.
20. Edwards R.P., Gooding W., Lembersky B.C., Colonello K., Hammond R., Paradise C., et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: Twenty-four-hour versus 7-day infusion. J Clin Oncol 1997; 15:3399-3407; PMID:9363872.
21. Vlad A.M., Budiu R.A., Lenzner D.E., Wang Y., Thaller J.A., Colonello K., et al. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother 2010; 59:293-301; PMID:19690855; DOI:10.1007/s00262-009-0750-3.
22. Hodi F.S., Butler M., Oble D.A., Seiden M.V., Haluska F.G., Kruse A., et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008; 105:3005-10; PMID:18287062; DOI:10.1073/pnas.0712237105.
23. Hodi F.S., Mihm M.C., Soiffer R.J., Haluska F.G., Butler M., Seiden M.V., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003; 100:4712-7; PMID:12682289; DOI:10.1073/pnas.0830997100.
24. Ramsdell F FoxP3 and natural regulatory T cells: key to a cell lineage? Immunity 2003; 19:165-8; PMID:12932350; DOI:10.1016/S1074-7613(03)00207-3.
25. Tsao S.W., Mok C.H., Knapp R.C., Oike K., Muto M.G., Welch W.R., et al. Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas. Gynecol Oncol 1993; 48:5-10; PMID:8423021; DOI:10.1006/gyno.1993. 1002.
26. Khalique L., Ayhan A., Weale M.E., Jacobs I.J., Ramus S.J., Gayther SA Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours J Pathol 2007; 211:286-95; PMID:17154249; DOI:10.1002/path.2112.
27. Khalique L., Ayhan A., Whittaker J.C., Singh N., Jacobs I.J., Gayther S.A., et al. The clonal evolution of metastases from primary serous epithelial ovarian cancers. Int J Cancer 2009; 124:1579-86; PMID:19123469; DOI:10.1002/ijc.24148.
28. Buller R.E., Skilling J.S., Sood A.K., Plaxe S., Baergen R.N., Lager DJ Field cancerization: why late "recurrent"ovarian cancer is not recurrent Am J Obstet Gynecol 1998; 178:641-9; PMID:9579425; DOI:10.1016/S0002-9378(98)70473-9.
29. Muto M.G., Welch W.R., Mok S.C., Bandera C.A., Fishbaugh P.M., Tsao S.W., et al. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res 1995; 55:490-492; PMID:7834614.
30. Donninger H., Bonome T., Radonovich M., Pise-Masison C.A., Brady J., Shih J.H., et al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 2004; 23:8065-77; PMID:15361855; DOI:10.1038/sj.onc.1207959.
31. Calza S., Valentini D., Pawitan Y Normalization of oligonucleotide arrays based on the least-variant set of genes BMC Bioinformatics 2008; 9:140; PMID:18318917; DOI:10.1186/1471-2105-9-140.
32. National Institute of Allergy and Infectious Diseases. ImmPort: Bioinformatics for the future of immunology. National Institute of Allergy and Infectious Diseases. Available at: www.immport.org.
33. Sokal R.R., Rohlf F.J. The comparison of dendrograms by objective methods. Taxon 1962; 11:33-40; DOI:10.2307/1217208.